HALIDE-FREE AMMONIUM SILANES

1 . A pharmaceutical composition comprising an excipient selected from Formula A and a compound of Formula B, wherein:

Formula A is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof;

wherein in Formula A:

a) R X is

 wherein R 2 is selected from the group consisting of hydrogen and C 1 -C 6 alkyl; or

b) R X is selected from

 wherein R 2 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, and —O—;

Formula B is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof;

wherein in Formula B:

each R is independently selected from the group consisting of OH, alkoxy, and Cl;

G is hydrogen, alkyl, aryl, cycloalkyl, heterocycle, heteroaryl, —CN, or CF 3 ;

each R 2 is selected from the group consisting of hydrogen and C 1 -C 6 alkyl;

R 3 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, and —O—;

X 1 is selected from the group consisting of a bond,

X 2 is selected from the group consisting of a bond,

Z is selected from the group consisting of alkyl, —NO 2 , —SO 3 H, —SO 2 H, —SO 3 − , —SO 3 M, —CO 2 H, —CO 2 − , —CO 2 M, phosphate, OH, NH 2 , and SH;

A − is absent or a non-halogen anion;

M is a metal cation; and

each n is independently selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, and 18.

2 . The pharmaceutical composition of claim 1 , wherein the excipient of Formula A is

or a pharmaceutically acceptable salt thereof.

3 . The pharmaceutical composition of claim 1 , wherein the excipient of Formula A is

or a pharmaceutically acceptable salt thereof.

4 . The pharmaceutical composition of claim 1 , wherein the ratio of molecules of Formula A to molecules of Formula B is about 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, or 4 to 1.

5 . The pharmaceutical composition of claim 1 , wherein the ratio of molecules of Formula A to molecules of Formula B is about 2.5, 2.75, 3, 3.25, 3.5, 3.75, or 4 to 1.

6 . The pharmaceutical composition of claim 1 , wherein there are about 3 molecules of Formula A for every one molecule of Formula B.

7 . The pharmaceutical composition of claim 1 , wherein the compound of Formula B is selected from the group consisting of:

8 . The pharmaceutical composition of claim 7 , wherein the excipient of Formula A is

or a pharmaceutically acceptable salt thereof.

9 . The pharmaceutical composition of claim 7 , wherein the excipient of Formula A is

or a pharmaceutically acceptable salt thereof.

10 . The pharmaceutical composition of claim 1 , wherein A − is selected from the group consisting of

chlorite, perchlorate, hydroxide, formate, acetate, lactate, benzoate, nitrate, and salicylate anion.

11 . The pharmaceutical composition of claim 1 , wherein G is H.

12 . The pharmaceutical composition of claim 1 , wherein n is 15.

13 . The pharmaceutical composition of claim 1 , wherein n is 16.

14 . The pharmaceutical composition of claim 1 , wherein n is 17.

15 . The pharmaceutical composition of claim 1 , wherein n is 18.

16 . The pharmaceutical composition of claim 1 , wherein R 2 is methyl.

17 . The pharmaceutical composition of claim 1 , wherein R 3 is methyl.

18 . A method for the treatment of an infection in a human or animal host, comprising administering to the host an effective amount of pharmaceutical composition of claim 1 .

19 . The method of claim 18 , wherein the infection is selected from the group consisting of an ocular infection, an ear infection, a skin infection, a hair infection, a nail infection, a chronic wound, a medical implant infection, a mouth infection, a nasal infection, a vaginal infection, a groin infection, a scalp infection, a uterine infection, an anal infection, and a combination thereof.

20 . The method of claim 19 , wherein the infection is caused by a bacterium, a fungus, an amoeba, a virus, or a combination thereof.